Desirable attributes of vaccines for deployment in low-resource settings

Journal of Pharmaceutical Sciences

Volumn 102, Issue 1, 2013, Pages 29-33

  Chen, Dexiang ^a   Zehrung, Darin ^a  

^a PATH   (United States)

Author keywords

Dose proportionality; Global health; Stability; Vaccine adjuvants; Vaccines

Indexed keywords

VACCINE;

ARTICLE; DRUG MANUFACTURE; FREEZE DRYING; HEAT; HUMAN; IMMUNIZATION; IMMUNOGENICITY; PRODUCT DEVELOPMENT; TEMPERATURE DEPENDENCE; THERMOSTABILITY;

EID: 84870658532     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23352     Document Type: Article

References (17)

1. UNICEF. 2011. Levels and trends in child mortality: Report. Accessed September 27, 2012, at: http://www.unicef.org/media/files/Child_Mortality_Report_2011_Final.pdf.
2. UNICEF. 2011. Immunization: Reducing measles mortality. Accessed September 27, 2012, at: http://www.unicef.org/immunization/index_measles.html.
3. Meningitis Vaccine Project Web Site. 2011. Accessed September 27, 2012, at: http://www.meningvax.org/timeline.php.
4. Cross RM, Kaplan C, McClean D. 1957. The heat resistance of dried smallpox vaccine. Lancet 1:446-448.
5. House JA, Mariner JC. 1996. Stabilization of rinderpest vaccine by modification of the lyophilization process. Dev Biol Stand 87:235-244.
6. Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. 2007. Freezing temperatures in the vaccine cold chain: A systematic literature review. Vaccine 25(20):3980-3986.
7. Kristensen D, Chen D, Cummings R. 2011.Vaccine stabilization: Research, commercialization, and potential impact. Vaccine 29(41):7122-7124.
8. Chen D, Kristensen D. 2009. Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines 8(5):547-557.
9. World Health Organization. 2012. Immunization service delivery: Project optimize. Accessed September 27, 2012, at: http://www.who.int/immunization_delivery/optimize/en/index.html.
10. UNICEF. 2011. Supplies and logistics: Vaccine price data. Accessed September 27, 2012, at: http://www.unicef.org/supply/index_57476.html.
11. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. 2009. Vaccine adjuvants: Current challenges and future approaches. J Pharm Sci 98(4):1278-1316.
12. PATH. 2009. Intradermal delivery of vaccines: A review of the literature and the potential for development for use in low- and middle-income countries. Accessed September 27, 2012, at: http://www.path.org/publications/detail.php?i=1746.
13. Icardi G, Orsi A, Ceravolo A, Ansaldi F. 2012. Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system. Hum Vaccin Immunother 8(1):67-75.
14. Alving CR, Peachman KK, Rao M, Reed SG. 2012. Adjuvants for human vaccines. Curr Opin Immunol 24(3):310-315.
15. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. 2010. New adjuvants for human vaccines. Curr Opin Immunol 22(3):411-416.
16. World Health Organization. 2010. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec 85:309-320.
17. Gruber MF. 2012. Regulatory pathways supporting development and approval of vaccines formulated with novel adjuvant: Regulatory considerations and challenges. Presented at Vaccine Forum Washington 2012. Accessed September 27, 2012, at: http://www.fda.gov/downloads/EmergencyPreparedness/MedicalCountermeasures/UCM292045.pdf.